Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous desmoglein-3 chimeric autoantibody receptor T cells DSG3-CAART

A preparation of autologous T lymphocytes that have been engineered to express a chimeric autoantibody receptor (CAAR) containing the autoantigen desmoglein-3 (desmoglein 3; DSG3) that is fused to the co-stimulatory domain of 4-1BB (CD137) and the T-cell receptor signaling domain of CD3zeta (CD3z), with potential immunomodulatory activity. Upon administration, the autologous DSG3 chimeric autoantibody receptor T cells (CAART) DSG3-CAART specifically recognize and induce selective toxicity in aberrant B cells expressing DSG3 autoantibodies. This inhibits the production of DSG3 autoantibodies. DSG3 is a protein expressed in desmosomes that plays an important role in cell adhesion. DSG3 autoantibodies are produced and expressed by aberrant B cells in the autoimmune disease mucosal-dominant pemphigus vulgaris.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous desmoglein 3 chimeric autoantibody receptor T cells DSG3-CAART
autologous desmoglein-3 CAAR-expressing T cells DSG3-CAART
autologous DSG3 CAART DSG3-CAART
autologous DSG3 chimeric autoantibody receptor T cells DSG3-CAART
DSG3 CAART
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search